A phase II study of crisnatol mesylate in patients with ovarian carcinoma.
Fourteen patients with advanced ovarian cancer received a 72 hour infusion of a new DNA intercalator, crisnatol mesylate, administered intravenously. There was no evidence of antitumor efficacy. A syndrome of nausea and vomiting associated with vertigo, dizziness and ataxia was observed in nearly all patients. Two of the patients developed severe CNS toxicity manifested in one by a grand-mal seizure and in the other by peripheral neuropathy. Further explorations into the potential efficacy of crisnatol mesylate administered intraperitoneally are underway.
Smalley
R V
RV
Clinical Cancer Center, University of Wisconsin.
Goldstein
D
D
Bulkowski
D
D
Hannon
C
C
Buchler
D
D
Knudsen
C
C
Tuttle
R L
RL
D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000187:drug effects; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000276:immunology; D002911:Chrysenes / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology; D011409:Propylene Glycols / Q000627:therapeutic use*; D016896:Treatment Outcome
D015295:Antigens, Tumor-Associated, Carbohydrate; D000970:Antineoplastic Agents; D002911:Chrysenes; D011409:Propylene Glycols; C056722:crisnatol